Rifaximin(Rifagut) is a semisynthetic antibiotic based on rifamycin. It has poor oral bioavailability meaning that very little of the drug will be absorbed into the blood stream when it is taken orally. Rifaximin is used in the treatment of traveler’s diarrhea and hepatic encephalopathy for which it received orphan drug status from the U.S. Food and Drug Administration in 1998.
This page contains content from the copyrighted Wikipedia article "Rifaximin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
